Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M48,735Revenue $M20,272Net Margin (%)13.4Z-Score2.4
Enterprise Value $M57,949EPS $3.6Operating Margin %17.4F-Score8
P/E(ttm))17.7Cash Flow Per Share $5.9Pre-tax Margin (%)15.9Higher ROA y-yY
Price/Book2.110-y EBITDA Growth Rate %13.5Quick Ratio0.8Cash flow > EarningsY
Price/Sales2.45-y EBITDA Growth Rate %10.9Current Ratio1.2Lower Leverage y-yY
Price/Cash Flow7.3y-y EBITDA Growth Rate %77.9ROA % (ttm)5.8Higher Current Ratio y-yY
Dividend Yield %2.4Insider Buy (3m)0ROE % (ttm)12.0Less Shares Outstanding y-yN
Payout Ratio %38.0Shares Outstanding M855ROI % (ttm)0.2Gross Margin Increase y-yY

Gurus Latest Trades with TEVA

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
TEVAJean-Marie Eveillard 2014-12-31 Add0.14%$49.86 - $58.72
($55.72)
$ 57.163%Add 72.35%2,448,310
TEVACharles Brandes 2014-12-31 Buy $49.86 - $58.72
($55.72)
$ 57.163%New holding, 3600 sh.3,600
TEVATom Gayner 2014-12-31 Sold Out -0.67%$49.86 - $58.72
($55.72)
$ 57.163%Sold Out0
TEVAGeorge Soros 2014-12-31 Reduce-0.55%$49.86 - $58.72
($55.77)
$ 57.162%Reduce -22.01%4,859,966
TEVANWQ Managers 2014-12-31 Reduce-0.39%$49.86 - $58.72
($55.72)
$ 57.163%Reduce -14.62%4,011,187
TEVANWQ Managers 2014-12-31 Reduce-0.39%$49.86 - $58.72
($55.72)
$ 57.163%Reduce -14.62%4,011,187
TEVAMichael Price 2014-12-31 Reduce-0.36%$49.86 - $58.72
($55.77)
$ 57.162%Reduce -10.5%447,500
TEVADavid Dreman 2014-12-31 Reduce-0.16%$49.86 - $58.72
($55.77)
$ 57.162%Reduce -23.89%119,838
TEVAJohn Keeley 2014-12-31 Reduce-0.01%$49.86 - $58.72
($55.72)
$ 57.163%Reduce -20.45%37,955
TEVAJean-Marie Eveillard 2014-09-30 Add0.19%$50.94 - $55.05
($52.93)
$ 57.168%Add 710190%1,420,580
TEVAGeorge Soros 2014-09-30 Reduce-0.42%$50.94 - $55.05
($52.93)
$ 57.168%Reduce -14.32%6,231,722
TEVATom Gayner 2014-09-30 Reduce-0.36%$50.94 - $55.05
($52.93)
$ 57.168%Reduce -36.02%444,000
TEVAVanguard Health Care Fund 2014-09-30 Reduce-0.27%$50.94 - $55.05
($52.93)
$ 57.168%Reduce -26.99%5,362,100
TEVANWQ Managers 2014-09-30 Reduce-0.21%$50.94 - $55.05
($52.93)
$ 57.168%Reduce -7.62%4,698,117
TEVARichard Snow 2014-06-30 Add0.21%$48.69 - $54.06
($51.09)
$ 57.1612%Add 6.9%1,826,799
TEVAGeorge Soros 2014-06-30 Reduce-1.59%$48.69 - $54.06
($51.09)
$ 57.1612%Reduce -29.45%7,273,240
TEVAVanguard Health Care Fund 2014-06-30 Reduce-0.73%$48.69 - $54.06
($51.09)
$ 57.1612%Reduce -40.54%7,344,400
TEVANWQ Managers 2014-06-30 Reduce-0.56%$48.69 - $54.06
($51.09)
$ 57.1612%Reduce -19.21%5,085,717
TEVAJames Barrow 2014-06-30 Reduce-0.19%$48.69 - $54.06
($51.09)
$ 57.1612%Reduce -18.5%10,868,770
TEVAKen Heebner 2014-06-30 Sold Out -0.13%$48.69 - $54.06
($51.09)
$ 57.1612%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

TEVA is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
TEVA Charles Brandes 2014-12-313,60000New Buy
TEVA Jean-Marie Eveillard 2014-12-312,448,3100.290.34+72.35%
TEVA James Barrow 2014-12-3110,823,1151.270.83+4.37%
TEVA Richard Snow 2014-12-311,856,7280.223.2+3.35%
TEVA Ronald Muhlenkamp 2014-12-31176,3850.022-0.27%
TEVA Vanguard Health Care Fund 2014-12-314,923,2000.580.66-8.19%
TEVA Michael Price 2014-12-31447,5000.053.1-10.5%
TEVA NWQ Managers 2014-12-314,011,1870.472.8-14.62%
TEVA John Keeley 2014-12-3137,95500.04-20.45%
TEVA George Soros 2014-12-314,859,9660.573.1-22.01%
TEVA David Dreman 2014-12-31119,8380.010.57-23.89%
TEVA Tom Gayner 2014-12-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


TEVA: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about TEVA :

Quarterly/Annual Reports about TEVA:

    News about TEVA:

    Articles On GuruFocus.com
    Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 
    Analysts are Bullish on IntelliPharmaceuticals Following Deal with Teva Pharmaceuticals Feb 04 2015 
    Weekly 52-Week Highs Highlight: ITW, ESRX, TEVA, CHD, STI Dec 08 2014 
    Zoetis in a Growing Global Animal Health Industry Dec 03 2014 
    Why Opko Health Is a Better Investment Than Apple Dec 02 2014 
    The Gurus’ Favorite Asian Stocks Sep 06 2014 
    George Soros Reveals His Largest Stake Jul 23 2014 
    George Soros Keeps Buying TEVA, EQT, YPF, EGN, CZR And Keeps Selling GOOGL, BA, MSFT, HAR Jul 16 2014 
    Diamond Hill Capital Comments on Teva Pharmaceutical Industries Ltd Jun 26 2014 
    Diamond Hill Select Fund Commentary – First Quarter 2014 Jun 25 2014 

    More From Our Partners
    Israel ETFs in Focus on Surprise Rate Cut - ETF News And Commentary Feb 26 2015 - ZACKS

    More From Other Websites
    Teva Announces Early Results of Debt Tender Offer, Pricing, Election of Early Settlement and... Feb 27 2015
    Teva Announces Early Results of Debt Tender Offer, Pricing, Election of Early Settlement and... Feb 27 2015
    Bayer will sell some St. Joseph animal health operations Feb 26 2015
    Israel ETFs in Focus on Surprise Rate Cut - ETF News And Commentary Feb 26 2015
    Teva to Present at the Cowen & Company 35th Annual Healthcare Conference Feb 26 2015
    Teva to Present at the Cowen & Company 35th Annual Healthcare Conference Feb 26 2015
    Teva Announces FDA Acceptance for Review of NDA for its Investigational Twice-Daily Hydrocodone... Feb 25 2015
    Teva Announces FDA Acceptance for Review of NDA for its Investigational Twice-Daily Hydrocodone... Feb 25 2015
    Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary... Feb 24 2015
    Central Bank Rate Cut, Loose Policies to Bolster Israel ETFs Feb 24 2015
    Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary... Feb 24 2015
    Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary... Feb 24 2015
    The Lancet Respiratory Medicine and AAAAI Publish Positive Data from Phase III Trials of Teva’s... Feb 23 2015
    Patents mean big business to big pharma Feb 23 2015
    The Lancet Respiratory Medicine and AAAAI Publish Positive Data from Phase III Trials of Teva’s... Feb 23 2015
    Teva to Present New Respiratory Data at 2015 Annual Meeting of the American Academy of Allergy,... Feb 20 2015
    Teva to Present New Respiratory Data at 2015 Annual Meeting of the American Academy of Allergy,... Feb 20 2015
    21st Century Cures: Waking Up Dormant Drug Therapies Feb 19 2015
    Teva Pharmaceutical Finance N.V. -- Moody's Affirms Teva's A3 rating; outlook changed to stable Feb 19 2015
    Alibaba Group Holding Ltd (BABA), Dow Chemical Co (DOW), and LyondellBasell Industries NV (LYB):... Feb 19 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK